OUR PRODUCTS

MOBILE APPS

GENERAL INFO

RLMD

Stock ticker: NASDAQ

PRICE

CHANGE

CAPITALIZATION

Relmada Therapeutics (RLMD) Earnings Date & Reports

Relmada Therapeutics Inc is a clinical-stage biotechnology company... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

RLMD is expected to report earnings to rise 50.00% to -44 cents per share on November 06

Relmada Therapeutics RLMD Stock Earnings Reports

Q3'25

Est.

$-0.45

Q2'25

Beat

by $0.10

Q1'25

Missed

by $0.21

Q4'24

Beat

by $0.09

Q3'24

Missed

by $0.04

The last earnings report on August 07 showed earnings per share of -30 cents, beating the estimate of -40 cents. With 244.61K shares outstanding, the current market capitalization sits at 21.95M.

View a ticker or compare two or three

Compare

RLMD

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For RLMD
(Try 14 days for Free)

Interact to see
Advertisement

A.I.Advisor

published price charts

These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. RLMD showed earnings on August 07, 2025. You can read more about the earnings report here.

View AI-Driven Trading

A.I. Advisor

published General Information

General Information

a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

2222 Ponce de Leon Boulevard

Phone

+1 786 629-1376

Employees

Web

https://www.relmada.com